Celldex Therapeutics (CLDX) : Traders are bullish on Celldex Therapeutics (CLDX) as it has outperformed the S&P 500 by a margin of 1.84% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.23%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.85% in the last 1 week, and is up 8.72% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Celldex Therapeutics (NASDAQ:CLDX): The stock was completely flat for the day, closing at $4.74 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $4.76, the stock touched an intraday high of $4.80 and a low of $4.70. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $4.74. The total trading volume on Friday was 1,381,792.
The stock has recorded a 20-day Moving Average of 4.66% and the 50-Day Moving Average is 8.82%. Celldex Therapeutics, Inc. is up 16.46% in the last 3-month period. Year-to-Date the stock performance stands at -69.77%.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.